Lexicon Pharmaceuticals updated on the Phase 3 SONATA-HCM trial testing sotagliflozin in symptomatic hypertrophic cardiomyopathy (HCM) patients. The trial enrolled 542 patients, exceeding its target, with a mix of obstructive and non-obstructive HCM cases, reflecting real-world clinical practice. Baseline symptom scores indicate significant patient burden, and the study aims to assess symptom improvement at 26 weeks. Topline results are expected in early 2027, potentially expanding treatment options for HCM, especially non-obstructive cases lacking FDA-approved therapies.
Lexicon Pharmaceuticals' Phase 3 SONATA-HCM trial update offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 23, 2026 18:41 WIB: out of 150 priced US health stocks, 31 rose and 112 fell. Notable movers include INO at USD 0.85 with 73% sell orders, SANA at USD 2.40 with 54% buy orders, and HCA at USD 462.05 with a typical hold time of 77 days.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
